Medicina
Departamento
Universidad Católica de Valencia San Vicente Mártir
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Universidad Católica de Valencia San Vicente Mártir (22)
2024
-
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Transplantation and Cellular Therapy, Vol. 30, Núm. 2, pp. 210.e1-210.e14
-
Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial
eClinicalMedicine, Vol. 71
2023
-
An update on the pathogenesis and diagnosis of thrombotic thrombocytopenic purpura
Expert Review of Hematology, Vol. 16, Núm. 1, pp. 17-32
-
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
Annals of Oncology, Vol. 34, Núm. 9, pp. 783-795
-
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 8, pp. 1557-1568
-
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
Blood cancer journal
-
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study
Journal of Geriatric Oncology, Vol. 14, Núm. 1
-
Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT)
British Journal of Haematology, Vol. 203, Núm. 5, pp. 860-871
-
Immune thrombotic thrombocytopenic purpura: clinical suspicion and basic management in emergency departments — an expert review and consensus statement from the Spanish societies of hematology and hemotherapy (SEHH) and emergency medicine (SEMES)
Emergencias, Vol. 35, Núm. 1, pp. 44-52
2022
-
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161
-
Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era
Annals of Hematology, Vol. 101, Núm. 1, pp. 59-67
2021
-
Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura
Expert Review of Hematology, Vol. 14, Núm. 8, pp. 707-719
-
The role of CDK4/6 inhibitors in early breast cancer
Breast, Vol. 58, pp. 160-169
2020
-
Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry
Revista Clinica Espanola, Vol. 220, Núm. 8, pp. 480-494
-
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Blood, Vol. 136, Núm. 2, pp. 199-209
-
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792
2016
-
Analysis of the immune microenvironment in resected non-small cell lung cancer: The prognostic value of different T lymphocyte markers
Oncotarget, Vol. 7, Núm. 33, pp. 52849-52861
2015
-
Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: Results of a prospective phase 2 Spanish/PETHEMA trial
Haematologica, Vol. 100, Núm. 8, pp. 1096-1102
-
Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma
Leukemia and Lymphoma, Vol. 56, Núm. 2, pp. 415-419
-
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations
Leukemia Research Reports, Vol. 4, Núm. 2, pp. 64-69